Dipexium Pharmaceuti (DPRX) 10.08 $DPRX
Dipexium Pharmaceuticals' Locilex® Microbiology Data Presented at ASM Microbe 2016 Conference
PR Newswire - Mon Jun 20, 3:01PM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), and research collaborator, R. M. Alden Research Laboratory, announced that data from two new Locilex® microbiology studies were presented at the American Society for Microbiology's Microbe conference in Boston, Massachusetts, June 16-20, 2016.
DPRX: 10.08 (+0.25)
Dipexium Announces Completion of Enrollment Objective in OneStep-1 Pivotal Phase 3 Clinical Trial
PR Newswire Europe - Mon May 16, 7:01AM CDT
Both Pivotal Phase 3 Clinical Trials Are Now Completed
DPRX: 10.08 (+0.25)
Dipexium Pharmaceuticals Announces Completion of Enrollment Objective in OneStep-2 Pivotal Phase 3 Clinical Trial and First Quarter 2016 Financial Results
PR Newswire - Thu May 12, 6:00AM CDT
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today announced that it has completed the patient enrollment objective in the OneStep-2 pivotal Phase 3 clinical trial in accordance with the requirements set forth in the OneStep-2 clinical trial protocol. The Company also announced that the OneStep-1 pivotal Phase 3 clinical trial has passed the 98% enrollment mark and is expected to reach the 180 patient enrollment objective imminently. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials conducted under a Special Protocol Assessment (SPA) agreement between the U.S. Food and Drug Administration (FDA) and Dipexium for evaluation of Locilex® for the treatment of patients with mild infections of diabetic foot ulcers (Mild DFI).
DPRX: 10.08 (+0.25)
Dipexium Pharmaceuticals to Hold First Quarter 2016 Financial Results Conference Call on Thursday, May 12, 2016, at 8:30 a.m. ET
PR Newswire - Mon May 09, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) will release its financial results for the quarter ended March 31, 2016, on Thursday, May 12, 2016 at 7:00 a.m. ET. The announcement will be followed by a conference call at 8:30 a.m. ET during which Dipexium management will discuss these results, recent developments and answer questions.
DPRX: 10.08 (+0.25)
Dipexium Pharmaceuticals (DPRX) Jumps: Stock Rises 7.5%
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 7:40AM CDT
Dipexium Pharmaceuticals, Inc. (DPRX) saw its shares rise above 7% in the last trading session.
DPRX: 10.08 (+0.25)
Will Dipexium Pharmaceuticals (DPRX) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 7:03AM CDT
As of late, it has definitely been a great time to be an investor in Dipexium Pharmaceuticals Inc (DPRX)
DPRX: 10.08 (+0.25)
Why You Shouldn't Bet Against Dipexium Pharmaceuticals (DPRX) Stock
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 7:52AM CDT
Dipexium Pharmaceuticals (DPRX) looks like an interesting choice for investors, as it is seeing solid estimate revisions and belongs to a great industry
DPRX: 10.08 (+0.25)
Dipexium Pharmaceuticals Announces Issuance of Locilex® Patent in Japan
PR Newswire - Mon Mar 28, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antimicrobial peptide, today announced that the government of Japan has issued a Locilex patent. The patent claims are directed to a novel formulation of Locilex, an antimicrobial peptide formulated as a topical cream. The issued patent has an expiry date in June 2033.
DPRX: 10.08 (+0.25)
Dipexium Pharmaceuticals Reports 2015 Financial Results
PR Newswire - Wed Mar 23, 6:00AM CDT
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antimicrobial peptide, today announced operational and financial results for the year ended December 31, 2015.
DPRX: 10.08 (+0.25)
Dipexium Pharmaceuticals to Hold Year End 2015 Financial Results Conference Call on Wednesday, March 23, 2016, 8:30 a.m. ET
PR Newswire - Mon Mar 14, 6:00AM CDT
Dipexium Pharmaceuticals (NASDAQ: DPRX) will release its financial results for the year ended December 31, 2015, on Wednesday, March 23, 2016 at approximately 7:00 a.m. ET. The announcement will be followed by a conference call at 8:30 a.m. ET during which Dipexium management will discuss these results, recent developments, and answer questions.
DPRX: 10.08 (+0.25)
Dipexium Progresses on Phase III Diabetic Foot Ulcer Studies
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 2:50PM CST
Dipexium (DPRX) attains 75% enrollment milestone in two phase III studies on Locilex for the treatment of patients with mild infections of diabetic foot ulcers.
DPRX: 10.08 (+0.25), OSIR: 5.03 (+0.17), LGND: 125.86 (+2.13), ANIK: 53.30 (+0.94)
Dipexium Pharmaceuticals Reaches 75% Enrollment Milestone in Pivotal Phase 3 Clinical Trials
PR Newswire - Thu Feb 04, 7:00AM CST
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today announced its OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone, in the aggregate, with each study having enrolled nearly the same number of patients. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials (180 patients per clinical trial) being conducted under a Special Protocol Assessment (SPA) agreement between the U.S. Food and Drug Administration and Dipexium for evaluation of Locilex® for the treatment of patients with mild infections of diabetic foot ulcers.
DPRX: 10.08 (+0.25)
Dipexium Pharmaceuticals Announces Issuance of Locilex® Patents in Australia and New Zealand
PR Newswire - Mon Feb 01, 7:00AM CST
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today announced that the governments of Australia and New Zealand have issued new Locilex patents. The patents' claims are directed to a novel formulation of Locilex, an antibiotic peptide formulated as a topical cream, and the use of Locilex as a method of treating skin or wound infections. Both issued patents have expiry dates in June 2033.
DPRX: 10.08 (+0.25)
Dipexium Pharmaceuticals Announces Presentation at 18th Annual BIO CEO & Investor Conference
PR Newswire - Fri Jan 29, 7:00AM CST
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced that David P. Luci, President & Chief Executive Officer, will present a corporate overview at the 18th Annual BIO CEO & Investor Conference in New York City, on Tuesday, February 9, 2015 at 9:30 a.m. Eastern Time.
DPRX: 10.08 (+0.25)
Dipexium Pharmaceuticals Announces Presentation at Biotech Showcase(TM) 2016
PR Newswire - Wed Jan 06, 6:00AM CST
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced that David P. Luci, President & Chief Executive Officer, will present a corporate overview at the Biotech Showcase(TM) 2016 Conference being held in San Francisco, California.
DPRX: 10.08 (+0.25)
Diabetic Foot Ulcers - Pipeline Review 2015
M2 - Wed Jan 06, 4:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/n92r2c/diabetic_foot) has announced the addition of the "Diabetic Foot Ulcers - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Adocia - Aprogen, Inc. - Bayer AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - CoDa Therapeutics, Inc. - CytoTools AG - Dipexium Pharmaceuticals LLC - EyeGene, Inc. - FirstString Research, Inc. - GlaxoSmithKline Plc - Human Stem Cells Institute - Innovaxis - Izun Pharmaceuticals Corporation - Karyopharm Therapeutics, Inc. - Lytix Biopharma AS - MediaPharma s.r.l. - MediWound Ltd. - NovaLead Pharma Pvt. Ltd. - Oneness Biotech Co., Ltd. - Osiris Therapeutics, Inc. - Plurogen Therapeutics, Inc. - Sanofi - Stratatech Corporation - TechnoPhage SA - TGV-Laboratories - Theravasc, Inc. - Tissue Med Biosciences - USV Limited For more information visit http://www.researchandmarkets.com/research/n9...betic_foot
DPRX: 10.08 (+0.25), OSIR: 5.03 (+0.17), MDWD: 7.88 (+0.07), GSK: 43.38 (+0.04), KPTI: 7.11 (+0.01), CELGZ: 1.43 (+0.08)
Dipexium Pharmaceuticals' Locilex® Microbiology Data Presented at ASM Microbe 2016 Conference
PR Newswire - Mon Jun 20, 3:01PM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), and research collaborator, R. M. Alden Research Laboratory, announced that data from two new Locilex® microbiology studies were presented at the American Society for Microbiology's Microbe conference in Boston, Massachusetts, June 16-20, 2016.
DPRX: 10.08 (+0.25)
Dipexium Announces Completion of Enrollment Objective in OneStep-1 Pivotal Phase 3 Clinical Trial
PR Newswire Europe - Mon May 16, 7:01AM CDT
Both Pivotal Phase 3 Clinical Trials Are Now Completed
DPRX: 10.08 (+0.25)
Dipexium Pharmaceuticals Announces Completion of Enrollment Objective in OneStep-2 Pivotal Phase 3 Clinical Trial and First Quarter 2016 Financial Results
PR Newswire - Thu May 12, 6:00AM CDT
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today announced that it has completed the patient enrollment objective in the OneStep-2 pivotal Phase 3 clinical trial in accordance with the requirements set forth in the OneStep-2 clinical trial protocol. The Company also announced that the OneStep-1 pivotal Phase 3 clinical trial has passed the 98% enrollment mark and is expected to reach the 180 patient enrollment objective imminently. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials conducted under a Special Protocol Assessment (SPA) agreement between the U.S. Food and Drug Administration (FDA) and Dipexium for evaluation of Locilex® for the treatment of patients with mild infections of diabetic foot ulcers (Mild DFI).
DPRX: 10.08 (+0.25)
Dipexium Pharmaceuticals to Hold First Quarter 2016 Financial Results Conference Call on Thursday, May 12, 2016, at 8:30 a.m. ET
PR Newswire - Mon May 09, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) will release its financial results for the quarter ended March 31, 2016, on Thursday, May 12, 2016 at 7:00 a.m. ET. The announcement will be followed by a conference call at 8:30 a.m. ET during which Dipexium management will discuss these results, recent developments and answer questions.
DPRX: 10.08 (+0.25)
Dipexium Pharmaceuticals (DPRX) Jumps: Stock Rises 7.5%
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 7:40AM CDT
Dipexium Pharmaceuticals, Inc. (DPRX) saw its shares rise above 7% in the last trading session.
DPRX: 10.08 (+0.25)
Will Dipexium Pharmaceuticals (DPRX) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 7:03AM CDT
As of late, it has definitely been a great time to be an investor in Dipexium Pharmaceuticals Inc (DPRX)
DPRX: 10.08 (+0.25)
Why You Shouldn't Bet Against Dipexium Pharmaceuticals (DPRX) Stock
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 7:52AM CDT
Dipexium Pharmaceuticals (DPRX) looks like an interesting choice for investors, as it is seeing solid estimate revisions and belongs to a great industry
DPRX: 10.08 (+0.25)
Dipexium Pharmaceuticals Announces Issuance of Locilex® Patent in Japan
PR Newswire - Mon Mar 28, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antimicrobial peptide, today announced that the government of Japan has issued a Locilex patent. The patent claims are directed to a novel formulation of Locilex, an antimicrobial peptide formulated as a topical cream. The issued patent has an expiry date in June 2033.
DPRX: 10.08 (+0.25)
Dipexium Pharmaceuticals Reports 2015 Financial Results
PR Newswire - Wed Mar 23, 6:00AM CDT
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antimicrobial peptide, today announced operational and financial results for the year ended December 31, 2015.
DPRX: 10.08 (+0.25)
Dipexium Pharmaceuticals to Hold Year End 2015 Financial Results Conference Call on Wednesday, March 23, 2016, 8:30 a.m. ET
PR Newswire - Mon Mar 14, 6:00AM CDT
Dipexium Pharmaceuticals (NASDAQ: DPRX) will release its financial results for the year ended December 31, 2015, on Wednesday, March 23, 2016 at approximately 7:00 a.m. ET. The announcement will be followed by a conference call at 8:30 a.m. ET during which Dipexium management will discuss these results, recent developments, and answer questions.
DPRX: 10.08 (+0.25)
Dipexium Progresses on Phase III Diabetic Foot Ulcer Studies
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 2:50PM CST
Dipexium (DPRX) attains 75% enrollment milestone in two phase III studies on Locilex for the treatment of patients with mild infections of diabetic foot ulcers.
DPRX: 10.08 (+0.25), OSIR: 5.03 (+0.17), LGND: 125.86 (+2.13), ANIK: 53.30 (+0.94)
Dipexium Pharmaceuticals Reaches 75% Enrollment Milestone in Pivotal Phase 3 Clinical Trials
PR Newswire - Thu Feb 04, 7:00AM CST
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today announced its OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone, in the aggregate, with each study having enrolled nearly the same number of patients. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials (180 patients per clinical trial) being conducted under a Special Protocol Assessment (SPA) agreement between the U.S. Food and Drug Administration and Dipexium for evaluation of Locilex® for the treatment of patients with mild infections of diabetic foot ulcers.
DPRX: 10.08 (+0.25)
Dipexium Pharmaceuticals Announces Issuance of Locilex® Patents in Australia and New Zealand
PR Newswire - Mon Feb 01, 7:00AM CST
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today announced that the governments of Australia and New Zealand have issued new Locilex patents. The patents' claims are directed to a novel formulation of Locilex, an antibiotic peptide formulated as a topical cream, and the use of Locilex as a method of treating skin or wound infections. Both issued patents have expiry dates in June 2033.
DPRX: 10.08 (+0.25)
Dipexium Pharmaceuticals Announces Presentation at 18th Annual BIO CEO & Investor Conference
PR Newswire - Fri Jan 29, 7:00AM CST
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced that David P. Luci, President & Chief Executive Officer, will present a corporate overview at the 18th Annual BIO CEO & Investor Conference in New York City, on Tuesday, February 9, 2015 at 9:30 a.m. Eastern Time.
DPRX: 10.08 (+0.25)
Dipexium Pharmaceuticals Announces Presentation at Biotech Showcase(TM) 2016
PR Newswire - Wed Jan 06, 6:00AM CST
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced that David P. Luci, President & Chief Executive Officer, will present a corporate overview at the Biotech Showcase(TM) 2016 Conference being held in San Francisco, California.
DPRX: 10.08 (+0.25)
Diabetic Foot Ulcers - Pipeline Review 2015
M2 - Wed Jan 06, 4:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/n92r2c/diabetic_foot) has announced the addition of the "Diabetic Foot Ulcers - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Adocia - Aprogen, Inc. - Bayer AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - CoDa Therapeutics, Inc. - CytoTools AG - Dipexium Pharmaceuticals LLC - EyeGene, Inc. - FirstString Research, Inc. - GlaxoSmithKline Plc - Human Stem Cells Institute - Innovaxis - Izun Pharmaceuticals Corporation - Karyopharm Therapeutics, Inc. - Lytix Biopharma AS - MediaPharma s.r.l. - MediWound Ltd. - NovaLead Pharma Pvt. Ltd. - Oneness Biotech Co., Ltd. - Osiris Therapeutics, Inc. - Plurogen Therapeutics, Inc. - Sanofi - Stratatech Corporation - TechnoPhage SA - TGV-Laboratories - Theravasc, Inc. - Tissue Med Biosciences - USV Limited For more information visit http://www.researchandmarkets.com/research/n9...betic_foot
DPRX: 10.08 (+0.25), OSIR: 5.03 (+0.17), MDWD: 7.88 (+0.07), GSK: 43.38 (+0.04), KPTI: 7.11 (+0.01), CELGZ: 1.43 (+0.08)
